Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity (2022 - 2023)

Historic Liabilities and Shareholders Equity for Therapeutics (LENZ) over the last 2 years, with Q3 2023 value amounting to $266.2 million.

  • Therapeutics' Liabilities and Shareholders Equity fell 2049.22% to $266.2 million in Q3 2023 from the same period last year, while for Dec 2023 it was $863.3 million, marking a year-over-year decrease of 3785.59%. This contributed to the annual value of $321.9 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2023, Therapeutics' Liabilities and Shareholders Equity is $266.2 million, which was down 2049.22% from $287.0 million recorded in Q2 2023.
  • Over the past 5 years, Therapeutics' Liabilities and Shareholders Equity peaked at $378.6 million during Q1 2022, and registered a low of $266.2 million during Q3 2023.